We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 10.50 | 0.62% | 1,715.50 | 1,714.50 | 1,715.50 | 1,720.50 | 1,695.50 | 1,705.00 | 1,689,836 | 14:40:30 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 14.31 | 70.5B |
From May 2019 to May 2024
By Oliver Griffin
GlaxoSmithKline PLC (GSK.LN) and Innoviva Inc. (INVA) on Wednesday reported positive headline results from a phase-three impact study of Trelegy Ellipta, a triple-therapy inhaler for patients with chronic obstructive pulmonary disease.
The Trelegy Ellipta is approved by the U.S. Food and Drug Administration and designed to be used once daily for long-term maintenance treatment.
GlaxoSmithKline said the Trelegy Ellipta study, which involved 10,355 patients, showed significant reductions in the annual rate of on-treatment exacerbations when compared with the dual-therapy treatments it has in its portfolio.
Write to Oliver Griffin at oliver.griffin@dowjones.com
(END) Dow Jones Newswires
September 20, 2017 03:00 ET (07:00 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
